Bora Pharmaceuticals Appoints Senior Vice President to Strengthen Global Sales and Marketing Function

Bora Pharmaceuticals, a leading full-service contract development and manufacturing organization (CDMO), has appointed Sally Langa as its new Global SVP Sales and Marketing to help drive the company’s continued growth and achieve its aggressive expansion plans.

Bringing a wealth of experience within the highly competitive contract manufacturing industry, Sally is recognized throughout the industry for delivering diverse and profitable growth. She has held several senior roles in some of the industry’s most prominent CDMOs.

2020120.Sally Langa-photo

Sally, who will report directly to Bobby Sheng, Bora’s Chairman and CEO, will be responsible for building the overarching strategy and roadmap for Bora Pharmaceutical’s CDMO services to help the company meet its ambitious growth targets globally, as well as maximizing the impact Bora’s Sales and Marketing function, she will also support on high priority accounts and play a broader leadership role within Bora.

Bobby Sheng, Chairman and CEO at Bora Pharmaceuticals commented: “We are delighted to be in a position to attract a person like Sally into the organization. At Bora we recognize that our growth and success depends on the quality and dedication of our people and Sally brings invaluable knowledge and experience to the team, and will drive us towards achieving our ambitious growth strategy.”
Commenting on her appointment Sally said, “I am truly excited and honored to join the Bora team. It’s an exciting time at Bora as the team continues to achieve impressive growth and deliver high quality services to their client base and I’m delighted to be a part of defining and driving the organization’s strategy going forward.”

Across its two sites in Taiwan, Bora offers a broad range of technologies to its global customer-base from development to large-scale manufacturing, packaging, distribution, tech transfer, stability studies, and product life cycle management. Bora acquired the Mississauga plant from GSK in late 2020. The site is the company’s first manufacturing facility in North America.